{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:14:54Z","timestamp":1791249294129,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cllc.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T19:00:09Z","timestamp":1663441209000},"page":"694-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-8627","authenticated-orcid":false,"given":"Kian C.","family":"Banks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ossowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yi","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.","family":"Ashiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Velotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Marie","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cllc.2022.09.003_bib0001","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: a population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2022.09.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.cllc.2022.09.003_bib0003","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2022.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.09.003_bib0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2017.08.009","article-title":"Patterns of care and survival among patients with malignant mesothelioma in the United States","volume":"112","author":"Enewold","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2022.09.003_bib0006","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jtcvs.2019.08.027","article-title":"Survival results in biphasic malignant pleural mesothelioma patients: a multicentric analysis","volume":"159","author":"Lococo","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2022.09.003_bib0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2020.05.032","article-title":"Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study","volume":"146","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2022.09.003_bib0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"Shaikh","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2022.09.003_bib0009","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1016\/j.ijrobp.2020.07.583","article-title":"A phase III randomized trial of pleurectomy\/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG-LU006)","volume":"108","author":"Rimner","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.cllc.2022.09.003_bib0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/SLA.0000000000004306","article-title":"Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients","volume":"275","author":"Lapidot","year":"2022","journal-title":"Ann Surg"},{"issue":"22","key":"10.1016\/j.cllc.2022.09.003_bib0011","first-page":"00352","article-title":"Outcomes of pleurectomy decortication in patients with biphasic mesothelioma","volume":"S0022-5223","author":"Lapidot","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.cllc.2022.09.003_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5761\/atcs.oa.10.01572","article-title":"Improving survival results after surgical management of malignant pleural mesothelioma: an australian institution experience","volume":"17","author":"Yan","year":"2011","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2022.09.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2022.09.003_bib0014","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2022.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/ijms23041975","article-title":"Novel and future treatment options in mesothelioma: a systematic review","volume":"23","author":"\u0160trbac","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10272","key":"10.1016\/j.cllc.2022.09.003_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.cllc.2022.09.003_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","article-title":"FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.09.003_bib0019","series-title":"How does the adult kaiser permanente membership in Northern California compare with the larger community?","author":"Gordon","year":"2006"},{"issue":"11","key":"10.1016\/j.cllc.2022.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.003_bib0021","unstructured":"Guidelines Detail. NCCN. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail. Accessed: April 2, 2022."},{"key":"10.1016\/j.cllc.2022.09.003_bib0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743","volume":"167","author":"Scherpereel","year":"2022","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2022.09.003_bib0023","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2022.09.003_bib0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.cllc.2022.09.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.cllc.2022.09.003_bib0026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.thorsurg.2020.08.002","article-title":"Taken together","volume":"30","author":"Song","year":"2020","journal-title":"Thorac Surg Clin"},{"issue":"13","key":"10.1016\/j.cllc.2022.09.003_bib0027","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:21Z","timestamp":1761506061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1525730422002029"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}